BLACK WEEKSFlakoni −15% · komplekti −10% · pārējais −5%ar koduBezmaksas piegāde Vācijā no €200

Šī lapa ir tulkota automātiski un var saturēt kļūdas. Vai latviešu valoda ir jūsu dzimtā valoda? Mēs labprāt saņemsim jūsu atsauksmes un labojumus.Sūtīt atsauksmi

The Peptide Desk The Peptide Desk
Reta + Tesamorelin Blend, produkta foto
GLP-1

Reta + Tesamorelin Blend

GLP-1

  • Sūtām no Vācijas

Pasūtījums

Vienības cena - Bezmaksas piegāde Vācijā no 200 € Black Weeks laikā
  • DHL ar izsekošanu
  • Diskrēts iepakojums

4.6 no 5 Trustpilot73 atsauksmes

Īsumā

Reta + Tesamorelin Blend skaitļos

Galvenie rādītāji no mūsu leksikona.

Pilns leksikona ieraksts
Type
Injectable blendtriple agonist + GHRH analog
Sizes
20 mg1 size in the shop
  1. Retatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)

    New England Journal of Medicine (PubMed PMID 37366315)
  2. Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)

    Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)
  3. Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)

    J Acquir Immune Defic Syndr (PubMed PMID 20101189)

Produktam Reta + Tesamorelin Blend vēl nav laboratorijas analīzes. Balsot par toPasūtiet testu, mēs apmaksājam pusiVisas laboratorijas analīzes

Zināšanas

Viss par Reta + Tesamorelin Blend

Noderēs

Kas jums vēl būs vajadzīgs

Bakteriostatiskais ūdens tiek automātiski pievienots grozam. Šļirces un salvetes - ar vienu klikšķi.

Insulīna šļirces

10 gab. · 5.50 €

Spirta salvetes

50 gab. · 10 €

Cik daudz ūdens?

Vienības uz šļirces jūsu flakona izmēram.

Atvērt kalkulatoru →

FAQ

Bieži uzdotie jautājumi

Avoti katrai atbildei: leksikona ieraksts

Vēl ir jautājums?

Rakstiet mums, mūsu komanda jums palīdzēs.

Is the Reta + Tesamorelin Blend approved or studied?

No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.

What is the catch with the fixed mix?

The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.

What do the Retatrutide trials show?

In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.

What do the tesamorelin trials show?

In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.

Which side effects were seen with the components?

Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.

Which trials are still running?

Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.

Saistītie

Saistītie produkti